Log in

Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis

  • Short Report
  • Published:
Journal of Inherited Metabolic Disease

Summary

Hyper-IgD and periodic fever syndrome (HIDS) is a hereditary autoinflammatory syndrome, characterized by recurrent inflammatory attacks. Treatment of HIDS is difficult. Recently, the IL-1ra analogue anakinra was reported to be successful in aborting the IgD inflammatory attacks in a vaccination model. We report a clinical case of spectacular reduction of febrile attacks in a severe HIDS patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Tsimaratos.

Additional information

Communicating editor: Georg Hoffmann

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cailliez, M., Garaix, F., Rousset-Rouvière, C. et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 29, 763 (2006). https://doi.org/10.1007/s10545-006-0408-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-006-0408-7

Keywords

Navigation